KCAS Bioanalytical & Biomarker Services

kcasbio.com

KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure in the field of bioanalysis/biomarker analysis of 22 years to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE JOINT VENTURE AND LICENSING AGREEMENTS

Mauna Kea Technologies | July 12, 2022

news image

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture. Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufact...

Read More

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

news image

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More

Pharma Tech

ANGELINI PHARMA SELECTS AIDEA’S ARTIFICIAL INTELLIGENCE TO BOOST ITS GROWTH

Angelini Pharma | March 11, 2021

news image

Trueblue, a main supplier of AI answers for Operational and Analytical CRM in the Life Science industry reports that Angelini Pharma, as a feature of a significant global computerized change measure, has picked AiDEA, the principal AI-Digital Cloud Pharma CRM arrangement dependent on Microsoft Dynamics 365. Angelini Pharma is a main pharmaceutical organization focused on aiding patients in the remedial zones of Central Nervous System (CNS) and Mental Health (including Pain), Rare Diseases and Co...

Read More

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFIC

Send Press Releases with GlobeNewswire | February 27, 2020

news image

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval. MAKScientific is a recognized ...

Read More
news image

Business Insights

TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE JOINT VENTURE AND LICENSING AGREEMENTS

Mauna Kea Technologies | July 12, 2022

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture. Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufact...

Read More
news image

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More
news image

Pharma Tech

ANGELINI PHARMA SELECTS AIDEA’S ARTIFICIAL INTELLIGENCE TO BOOST ITS GROWTH

Angelini Pharma | March 11, 2021

Trueblue, a main supplier of AI answers for Operational and Analytical CRM in the Life Science industry reports that Angelini Pharma, as a feature of a significant global computerized change measure, has picked AiDEA, the principal AI-Digital Cloud Pharma CRM arrangement dependent on Microsoft Dynamics 365. Angelini Pharma is a main pharmaceutical organization focused on aiding patients in the remedial zones of Central Nervous System (CNS) and Mental Health (including Pain), Rare Diseases and Co...

Read More
news image

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFIC

Send Press Releases with GlobeNewswire | February 27, 2020

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval. MAKScientific is a recognized ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us